Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
ARTBIO Inc.
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Male participants at least 18 years of age
ECOG PS of 0 to 2
Progressive mCRPC
Previous treatment with at least one novel ARPI
Prior orchiectomy and/or prior or ongoing androgen-deprivation therapy
Prior treatment with at least one taxane regimen or patient refusing or considered appropriate by treating physician to delay taxane therapy
177Lu-PSMA experienced Group only: Prior treatment with at least one dose of 177Lu-PSMA
At least one PSMA-avid distant metastatic lesion
Adequate bone marrow, renal, and hepatic function
You may not be if
Blockage in the bladder or kidneys
Untreated or uncontrolled brain metastases. Treated brain metastases are permitted provided they are neurologically stable
Symptomatic, or clinical or radiologic findings indicative of impending cord compression.
History of myelodysplastic syndrome (MDS), treatment-related acute myeloid leukaemia or features suggestive of MDS/acute myeloid leukaemia.
A known additional malignancy that has required active treatment within the past two years before start of study treatment, except for adequately treated basal or squamous cell carcinoma of the skin, or carcinoma in situ that has undergone curative therapy
